A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2007

Primary Completion Date

October 1, 2007

Study Completion Date

October 1, 2007

Conditions

Psoriasis

Interventions

DRUG

Navarixin 10 mg

Navarixin capsules orally, once daily for 28 days.

OTHER

Placebo

Matching placebo capsules to Navarixin orally, once daily for 28 days.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00684593 - A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009) | Biotech Hunter | Biotech Hunter